26 jul: Statoil Q2: Dobbelt så godt som ventet
26 jul: Råvarer: Større lagre sender olieprisen på retur
26-07-2012 07:54:00

Sanofi Second-Quarter Net Profit up 16% Boosted by Tax Effect

Relateret indhold
Relateret debat
19 sep - 
Udfordring for Sanofi, ikke Novo, der jo har er bedre p..
19 sep - 
Hvordan kan Sanofi kræve at kopier ikke markedsføres fø..
19 sep - 
Og mon ikke afgørelsen bliver præcis som den Eli Lily f..

By Noemie Bisserbe

PARIS--France's top drug maker Sanofi SA (SNY, SAN.FR) said Thursday it expected its earnings to fall this year, dented by the loss of patents on some of its blockbuster drugs, even as it posted a firm increase in second-quarter net profit, boosted by a tax effect.

The Paris-based pharmaceutical major said net profit attributable to shareholders rose 16% to 1.17 billion euros (US$1.4 billion) in the quarter ended June 30, from EUR1.01 billion a year earlier.

Business net income--the term it uses for adjusted income excluding items such as impacts associated with acquisitions and divestments--was, however, down 9.6% to EUR1.94 billion, hit by the loss of its patents on top-selling drugs--blood thinner Plavix and Avapro, a drug used to treat high blood pressure.

Analysts had forecast a second-quarter business net profit of EUR1.88 billion.

Sanofi's woes underscore drug makers' growing difficulty in keeping their heads above water as they swim from one blockbuster drug to another. On Wednesday, GlaxoSmithKline PLC (GSK), Bristol-Myers Squibb Co. (BMY) and Eli Lilly & Co. (LLY) reported sharp drops in second-quarter net profit, hit by a wave of patent expirations for top-selling drugs.

Sanofi maintained its full-year guidance for a 12% to 15% decline in business earnings per share in 2012, assuming no major changes in exchange rates.

Analysts, however, expect Sanofi's earnings to rebound from 2013, as the group strives to rely less on innovative drug sales.

Sanofi, which is struggling with patent expirations, has been extending its pharmaceutical business to growth areas such as emerging markets, vaccines, diabetes solutions, consumer health care, innovative products and animal health, in a bid to become less dependent on patented medicines.

Net sales rose 6.2% to EUR8.87 billion, with revenue at the flagship pharmaceutical division increasing 5.1% to EUR7.5 billion.

Write to Noemie Bisserbe at noemie.bisserbe@dowjones.com

Order free Annual Report for Sanofi

Visit http://djnweurope.ar.wilink.com/?ticker=US80105N1054 or call +44 (0)208 391 6028

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

(END) Dow Jones Newswires

July 26, 2012 01:54 ET (05:54 GMT)

Copyright (c) 2012 Dow Jones & Company, Inc.

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
Ingen indlæg

Aktier/tendens: Opec-aftale kan gavne Mærsk og markedet under et

29-09-2016 08:17:55
A.P. Møller-Mærsk kan torsdag få medvind fra et pænt prishop på olie. Opec-landene enedes onsdag aften om at trimme produktionen, og det har sendt olieprisen i ..

Mærsk fortæller mere om ny strategi den 13. december

28-09-2016 15:49:11
A.P. Møller-Mærsk afholder sin tidligere udsatte kapitalmarkedsdag den 13. december. Det fremgår af selskabets hjemmeside.Mærsk udsatte sin kapitalmarkedsdag på..

Mærsk og kolleger undersøges for containerkartel i Sydafrika - NY

28-09-2016 12:35:22
De sydafrikanske konkurrencemyndigheder har indledt undersøgelser af seks af verdens største containerrederier - herunder lokale datterselskaber af A.P. Møller-..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge
1
Novo Nordisk vil afskedige 1000 medarbejdere - heraf 500 i Danmark -NY
2
Nets: Verdens største kapitalforvalter er nu storaktionær
3
Aktier/tendens: Opec-aftale kan gavne Mærsk og markedet under et
4
Bavarian ansætter ny medicinsk direktør
5
IMF slår alarm over handelsstop og lav inflation - citat

Relaterede aktiekurser

Sanofi 69,07 1,1% Stigning i aktiekurs
Sanofi American Deposita.. 38,67 0,0% Aktiekurs uændret

Køb- og salgsanbefalinger

  • Trend
  • Pengemaskinen

Copyright Euroinvestor A/S 2016  Disclaimer Privatlivspolitik
Aktieinformation leveres af Interactive Data.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
29. september 2016 10:24:23
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20160921.1 - EUROWEB3 - 2016-09-29 10:24:23 - 2016-09-29 10:24:23 - 1 - Website: OKAY

Når du besøger Euroinvestor.dk accepterer du, at der anvendes cookies, som vi og vores samarbejdspartnere benytter til funktionalitet, statistik og markedsføring. Læs mere om cookies på Euroinvestor.dk her

x